



REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

September 27, 2022 11:05 AM EDT

ROCKVILLE, Md., Sept. 27, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will present in a fireside chat at Chardan's 6th Annual Genetic Medicines Conference on Tuesday, October 4th, 2022:

Chardan's 6th Annual Genetic Medicines Conference

Date: Tuesday, October 4th, 2022

Fireside chat: 1:30 p.m. ET

Location: Westin Grand Central, New York, NY

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available in the Investors section of REGENXBIO's website for approximately 30 days following the presentation.

About REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates, including late-stage and commercial programs, in multiple therapeutic areas. REGENXBIO is committed to a "5x'25" strategy to progress five AAV Therapeutics from our internal pipeline and licensed programs into pivotal-stage or commercial products by 2025.


Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com

Investors:

Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com



 View original content to download multimedia: <https://www.prnewswire.com/news-releases/regenxbio-announces-presentation-at-chardans-6th-annual-genetic-medicines-conference-301633825.html>

SOURCE REGENXBIO Inc.